PFE

17 atoms · 跨 3 天 · 首见 2026-05-05 · 最近 2026-06-22

三色: 🟦 fact 15 · 🟥 take 2 · stance ▲2/▼2/◆2

来源: X 17

时态: fresh:15 · aging:2

标签: 好数字:12 · 好信源:3 · 好观点:2

叙事 (narrative) (2)

• 2026-05-05 [老化中] · management says reaffirming full-year guidance
  Today, we are reaffirming our full-year 2026 financial guidance.
  tags: 好信源 · → daily
• 2026-05-05 [老化中] · management says Q1 strong start
  We're off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer.
  tags: 好观点 · → daily

预测 (forecast) (1)

• 2026-05-05 · management says oncology and obesity are areas to lead
  I'm particularly encouraged by what we're seeing in oncology and obesity, two areas where I believe Pfizer is positioned to lead.
  tags: 好观点 · → daily

事实 (fact) (14)

• 2026-06-22 · Phase 3 trial of sigvotatug vedotin in previously treated metastatic NSCLC missed overall survival goal versus docetaxel
  PFIZER'S PHASE 3 TRIAL OF SIGVOTATUG VEDOTIN IN PREVIOUSLY TREATED METASTATIC NSCLC MISSED ITS OVERALL SURVIVAL GOAL VERSUS DOCETAXEL
  tags: 好信源 · → daily
• 2026-06-18 · CFO离职
  Chief Financial Officer Dave Denton will step down and leave the company on Aug. 15
  tags: 好信源 · → daily
• 2026-05-05 · 2026Q1 每股收益（EPS）
  实际每股收益 (Actual EPS): 0.75
  tags: 好数字 · → daily
  value: qty=0.75 · date=2026Q1
• 2026-05-05 · 2026Q1 营收
  实际营收 (Actual Revenue): 14.50B
  tags: 好数字 · → daily
  value: qty=14.50B · date=2026Q1
• 2026-05-05 · 2026Q1 营收同比变化
  营收同比变化 (Revenue YoY): 5%
  tags: 好数字 · → daily
  value: qty=5% · direction=YoY
• 2026-05-05 · Q1 revenue
  Revenue: $14.5B (Est. $13.84B) 🟢; +5% YoY, +2% operational
  tags: 好数字 · → daily
  value: qty=$14.5B · date=Q1 2026
• 2026-05-05 · Q1 adjusted EPS
  Adj. EPS: $0.75 (Est. $0.72)
  tags: 好数字 · → daily
  value: qty=$0.75 · date=Q1 2026
• 2026-05-05 · revenue ex-Comirnaty/Paxlovid growth
  Revenue Ex-Comirnaty/Paxlovid: +7% operational
  tags: 好数字 · → daily
  value: qty=+7% operational · date=Q1 2026
• 2026-05-05 · launched & acquired product revenue growth
  Launched & Acquired Product Revenue: +22% operational
  tags: 好数字 · → daily
  value: qty=+22% operational · date=Q1 2026
• 2026-05-05 · full-year revenue guidance
  Revenue: $59.5B-$62.5B
  tags: 好数字 · → daily
  value: qty=$59.5B-$62.5B · date=FY 2026
• 2026-05-05 · full-year adjusted EPS guidance
  Adj. EPS: $2.80-$3.00 (Est. $2.96)
  tags: 好数字 · → daily
  value: qty=$2.80-$3.00 · date=FY 2026
• 2026-05-05 · Q1 Padcev growth
  Padcev: +39% operational
  tags: 好数字 · → daily
  value: qty=+39% operational · date=Q1 2026
• 2026-05-05 · Q1 Comirnaty growth
  Comirnaty: -59% operational
  tags: 好数字 · → daily
  value: qty=-59% operational · date=Q1 2026
• 2026-05-05 · Q1 Paxlovid growth
  Paxlovid: -63% operational
  tags: 好数字 · → daily
  value: qty=-63% operational · date=Q1 2026

时间轴 (近 20)

• 2026-06-22 · fact · Phase 3 trial of sigvotatug vedotin in previously treated me · → daily
• 2026-06-18 · fact · CFO离职 · → daily
• 2026-05-05 · fact · 2026Q1 每股收益（EPS） · → daily
• 2026-05-05 · fact · 2026Q1 营收 · → daily
• 2026-05-05 · fact · 2026Q1 营收同比变化 · → daily
• 2026-05-05 · fact · Q1 revenue · → daily
• 2026-05-05 · fact · Q1 adjusted EPS · → daily
• 2026-05-05 · fact · revenue ex-Comirnaty/Paxlovid growth · → daily
• 2026-05-05 · fact · launched & acquired product revenue growth · → daily
• 2026-05-05 · fact · full-year revenue guidance · → daily
• 2026-05-05 · fact · full-year adjusted EPS guidance · → daily
• 2026-05-05 · fact · Q1 Padcev growth · → daily
• 2026-05-05 · fact · Q1 Comirnaty growth · → daily
• 2026-05-05 · fact · Q1 Paxlovid growth · → daily
• 2026-05-05 · narrative · management says Q1 strong start · → daily
• 2026-05-05 · forecast · management says oncology and obesity are areas to lead · → daily
• 2026-05-05 · narrative · management says reaffirming full-year guidance · → daily

← 实体目录 · 系统日志